Kooperativer Bibliotheksverbund

In: Annals of Hematology, Springer Science and Business Media LLC, Vol. 93, No. 2 ( 2014-2), p. 233-242

Type of Medium: Online Resource

ISSN: 0939-5555 , 1432-0584

URL: Article

DOI: 10.1007/s00277-013-1860-8

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2014

detail.hit.zdb_id: 1458429-3

In: Bone Marrow Transplantation, Springer Science and Business Media LLC, Vol. 55, No. 6 ( 2020-06), p. 1076-1084

Type of Medium: Online Resource

ISSN: 0268-3369 , 1476-5365

URL: Article

DOI: 10.1038/s41409-020-0783-y

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2020

detail.hit.zdb_id: 2004030-1

In: The Lancet Oncology, Elsevier BV, Vol. 20, No. 2 ( 2019-02), p. 202-215

Type of Medium: Online Resource

ISSN: 1470-2045

URL: Article

DOI: 10.1016/S1470-2045(18)30784-8

Language: English

Publisher: Elsevier BV

Publication Date: 2019

detail.hit.zdb_id: 2049730-1

In: Haematologica, Ferrata Storti Foundation (Haematologica), Vol. 101, No. 4 ( 2016-04), p. 466-473

Type of Medium: Online Resource

ISSN: 0390-6078 , 1592-8721

URL: Article

DOI: 10.3324/haematol.2015.134213

Language: English

Publisher: Ferrata Storti Foundation (Haematologica)

Publication Date: 2016

detail.hit.zdb_id: 2186022-1

detail.hit.zdb_id: 2030158-3

detail.hit.zdb_id: 2805244-4

In: Blood, American Society of Hematology, Vol. 118, No. 21 ( 2011-11-18), p. 3027-3027

Abstract: Abstract 3027 Patients (pts) with advanced/aggressive NHL who relapse after autologous stem cell transplantation (auto-sct) or who fail to respond to front-line chemotherapy have a very bad prognosis with a poor survival. We performed a prospective and multicentre study (Clinical Trials.gov, NCT 00607854) to evaluate the tolerability and the benefit of Zevalin added to a fludarabine-based RIC followed by allogenic stem cell transplantation (allo-sct) in pts with a poor prognosis lymphoma. Between January 2008 and October 2010, 30 pts under 65 years old with NHL in relapse after at least 2 previous regimen with or without auto-sct underwent an allo-sct with this preparative regimen. The underlying disease was DLBCL (10 pts), MCL (9 pts) and low grade lymphoma (FL=9 and MZL=2). Patients had to be in CR or PR after the last salvage regimen (Cheson criteria) and to have a HLA-compatible (10/10) match-related (MRD) or unrelated (MUD) donor or 9/10 mismatched UD. GVH prophylaxis was based on CsA alone or in combination with Methotrexate in case of mismatch. The primary objective of the study was TRM at day 100. All the pts are evaluable Twenty two were male (73%) and the median age was 57 (32–64). Twenty nine pts (97%) had prior auto-sct. Twenty pts were transplanted from a sibling donor, 8 from MUD and 2 pts had a C or DQ mismatch. At time of allo-sct, 18 pts were in CR and 12 pts in PR. Median time between diagnosis and allo-sct and between auto-sct and allo-sct was 36 mo and 18 mo respectively. Four pts died from a-GVH (n=2) at d 40 and 70, multi-organ failure (n=1) at d 117 and disease progression (n=1) at d 114 respectively. The TRM up to day 100 was 7% (n = 2). The median follow-up is 16 mo (9–40). All pts had a rapid and sustained engraftment. Twenty five pts are alive in CR. One pt died in CR (suicide) one year after transplant. The actuarial 3-year event-free and overall survival are 83% (± 6%). Estimated EFS at 2 years for the 3 different subgroups of diagnosis are 100% for FL and MZL, 89% (± 10%) for MCL and 70% (± 14%) for DLBCL. We conclude that Yttrium-90-ibritumomab tiuxetan (Zevalin) in combination with a fludarabine-based regimen is safe with a very low TRM rate. The results we report here are in pts with a very bad prognosis are very encouraging with a very high response rate and survival. Disclosures: Off Label Use: Zevalin not licensed in France in this indication. Zevalin has been kindly provided by BayerHealthcare company for the study.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V118.21.3027.3027

Language: English

Publisher: American Society of Hematology

Publication Date: 2011

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 4565-4565

Abstract: Abstract 4565 Background: The outcome of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) is very poor despite aggressive treatments or novel therapeutic agents. Allogenic STC (allo-STC) remains the only curative approach with an interesting reduced treatment-related-mortality (TRM) commonly associated with reduced intensity conditioning regimens (RIC). Radio immunotherapy (RIT) as part of conditioning regimen for autologous stem cell transplantion (ASCT) as well as for allo-SCT has demonstrated its safety and many studies are now suggesting an improved outcome. This phase II study (ClinicalTrials.gov: NCT 00607854) evaluated the safety and efficacy of Yttrium-90 ((90)-Y)-ibritumomab tiuxetan in combination with a fludarabine-based RIC followed by allo-SCT in patients with relapsed or chemorefractory CD 20 positive non-Hodgkin's lymphoma. Patients and Method: Patients with relapsed or refractory CD 20 positive NHL where eligible for the study if they had a sensitive disease (at least partial response) to the last salvage regimen and a suitable donor: related (RD) or unrelated donor (MUD or with a C or DQ mismatch). Each patient received a single dose of ((90)-Y)-ibritumomab tiuxetan (0,4 mci/Kg on day -14) followed from day -6 by a combination of fludarabine (30 mg/m2 d -6 to d -2), busilvex ((3,2 mg/Kg d -5 and d -4) and antithymocyte globulin (2,5 mg/Kg d -1). GVH prophylaxis was based on cyclosporine (CsA) alone or in combination with methotrexate (Mtx) in case of mismatched unrelated donor. The trial was designed to enroll 30 evaluable pts and the study started on January 2008. At time of this writing, 27 pts have been included and we report the preliminary results of the first 14 consecutive pts. The primary objective (PO) of the study was to evaluate the day 100 TRM. Secondary objectives were response (CR, PR) and event-free survival at 1 year. RESULTS: Fourteen pts are evaluable for the PO. The median age was 55 years (35-60), and the sex ratio (M/F) 10/4. Prior disease was DLBCL (5), MCL (4), FL (5). Pts received a median number of 2 previous treatment regimens and all pts had undergone ASCT before. Median time between diagnosis and allo-SCT and between ASCT and allo-SCT were 39 mo (range 8 – 106) and 14, 5 mo (range 3–52) respectively. At time of transplant 10 pts were in CR and 4 in PR. There were 10 RD and 4 MUD transplants. All pts received peripheral blood stem cells transplantation and GVH prophylaxis with CsA alone. Two pts died from a-GVH at day 40 and 117 post-transplant respectively with a TRM at day 100 of 7%. Both were in CR. The median time to ANC engraftment (ANC 〉 500/mm3) was 17 days (range 12 – 22) and time to platelets engraftment (Plt 〉 20.000/mm3) was 11 days (range 0–16). Acute GVH occurred in 7 pts with only 3 pts with grade ≥ 2. At day 100 after transplantation, 8 out of the 10 (80%) evaluable pts achieved a complete T-cell donor chimerism. With a median follow-up of 10 month (range 6 – 26), 12 pts are alive and in CR. The estimated event-free survival at 1year is 86% (CI 78% - 94%). CONCLUSION: ((90)-Y)-ibritumomab tiuxetan is safe and well tolerated when used in combination with a fludarabine-based RIC regime. Preliminary data suggest that the TRM is not increased by adding RIT in this conditioning regimen. Disclosures: Bouabdallah: Bayer Healthcare: The Trial has been partially sponsored by Bayer Healthcare. Off Label Use: Zevalin is off-label use in conditioning regimen in France.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V116.21.4565.4565

Language: English

Publisher: American Society of Hematology

Publication Date: 2010

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 23 ( 2013-08-10), p. 2912-2919

Abstract: Obinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, was superior to rituximab in human diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL) xenograft models. In phase I of our study, obinutuzumab (GA101) exhibited encouraging activity but no clear dose-response relationship, and few patients had aggressive histologies. The efficacy and safety of two doses of obinutuzumab (GA101) were explored in our randomized phase II trial in patients with heavily pretreated DBLCL and MCL. Patients and Methods Patients were randomly assigned to receive eight cycles of obinutuzumab (GA101) either as a flat dose of 400 mg for all infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 to 8) or 1,600 mg on days 1 and 8 of cycle 1 and 800 mg on day 1 of cycles 2 to 8. Results Forty patients were enrolled: 21 patients in the 400/400-mg treatment arm (DLBCL, n = 10; MCL, n = 11) and 19 patients in the 1,600/800-mg arm (DLBCL, n = 15; MCL, n = 4). End-of-treatment response was 28% (32% and 24% in the 1,600/800-mg and 400/400-mg study arms, respectively). Best overall response rates were 37% in the 1,600/800-mg arm and 24% in the 400/400-mg study arm (DLBCL, eight [32%] of 25 patients; MCL, four [27%] of 15 patients). Five (20%) of 25 rituximab-refractory patients exhibited treatment response, including four of 12 in the 1,600/800-mg group. The most common adverse events were infusion-related reactions (IRRs), which were manageable. Three patients had grade 3/4 IRRs. Grade 3/4 neutropenia was seen in only one patient. Conclusion Obinutuzumab (GA101) 1,600/800 mg achieves early steady-state concentration and clinical activity with an acceptable safety profile in relapsed/refractory DLBCL and MCL, supporting further exploration.

Type of Medium: Online Resource

ISSN: 0732-183X , 1527-7755

URL: Article

DOI: 10.1200/JCO.2012.46.9585

Language: English

Publisher: American Society of Clinical Oncology (ASCO)

Publication Date: 2013

detail.hit.zdb_id: 2005181-5

In: Blood, American Society of Hematology, Vol. 126, No. 23 ( 2015-12-03), p. 577-577

Abstract: BACKGROUND Escalated BEACOPP (BEAesc) demonstrated a better disease control than ABVD but no overall survival (OS) improvement in patients with advanced Hodgkin Lymphoma (HL) (Federico et al , J Clin Oncol 2009, Viviani et al, N Engl J Med 2011, Mounier et al, Ann Oncol 2014). The superior efficiency of BEAesc is associated to a substantially higher immediate hematological toxicity, and an increased risk of secondary myelodysplasia/leukemia and infertility. So, to better manage HL treatment there is a need to identify early responding patients able to benefit from a strategy of dose intensity de-escalation after upfront BEAesc, without impairing the disease control. PET performed after 2 cycles of chemotherapy (PET2) might identify such a population suitable for receiving ABVD after 2 cycles of upfront BEAesc, and was implemented in the present study. METHODS The AHL 2011 trial (NCT01358747) was designed to evaluate in 16 to 60 years old HL patients with Ann Arbor stage III, IV or high risk IIB, a treatment strategy driven by PET after 2 BEAesc cycles (PET2), delivering 4 cycles of ABVD for PET2 negative patients and 4 cycles of BEAesc for PET2 positive patients. This PET-driven strategy was randomly compared to a standard treatment not monitored by PET and delivering 6 cycles of BEAesc. A baseline PET was mandatory before treatment and PET2 were centrally reviewed and interpreted according to Deauville criteria within 48 hours. The allocation of treatment in the experimental arm was based on the PET2 central review results. PFS was the primary endpoint of the study with a hypothesis of non-inferiority of the PET driven arm compared to the standard arm with a margin of 10% (85% 5y-PFS in the standard arm vs 〉 75% in the PET driven arm). An interim analysis of the primary endpoint was planned after 50% (n = 49) of the 97 scheduled events needed for the final analysis. RESULTS From May 2011 to May 2014, 823 patients were registered and 782 were eligible for the interim analysis including 401 patients in the arm A, and 381 in arm B. Patients characteristics were well balanced in both arms: median age was 30 years (16 - 60), 64% were male, 81% had nodular sclerosis and 12% mixed cellularity HL, 12% had stage IIB, 28% stage III, 60% stage IV, and 58% had an international prognosis score ≥3. After 2 cycles of BEAesc PET was positive in 97 (12%) patients and PET2 positivity was similar in the standard and experimental arms (n = 48, 12% and n = 49, 13% respectively). Based on PET2 results, 319 (84%) patients received 4 cycles of ABVD and 49 (13%) 4 additional cycles of BEAesc in the experimental arm. Grade ≥3 toxicity was significantly higher in patients receiving 6 cycles of BEAesc compared to those who received 2 cycles of BEAesc + 4 cycles of ABVD with more frequent anemia (11% vs 2%), leukopenia (85% vs 72%), thrombocytopenia (44% vs 13%), febrile neutropenia (6% vs 3%), and sepsis (7% vs 4%). 182 serious adverse events (SAE) related to treatment occurred in 108 (24%) patients treated with 6 cycles of BEAesc (leading to death in 4 cases), compared to 72 SAE (leading to death in 1 case) in 50 (15%) patients treated with 2 x BEAesc + 4 x ABVD (p 〈 0.002). In these latter patients most of SAE (67%) occurred during the 2 first cycles of chemotherapy. With a median follow up of 16.3 months, in an intent to treat basis, the estimated 2y-PFS was similar in the standard (91.6%) and the PET driven arms (88.3%; p = 0.79). PET2 positivity was related to a significantly lower 2y-PFS compared to PET2 negative patients in the whole population (72.9% vs 92.8%; p 〈 0.0001) and in both randomization arms (75.1% vs 94% and 70.8% vs 91.6% in the standard and PET driven arms, respectively; p 〈 0.0001 for both). Overall survival was similar in both randomization arms and in PET2 positive or negative subsets of patients. CONCLUSIONS This interim analysis suggests that PET performed after 2 cycles of BEAesc can be safely used to guide subsequent treatment and supports the response-adapted strategy delivering 4 cycles of ABVD for patients with negative PET2 (84%) without impairing the disease control. This approach allows to significantly reduce the treatment-related immediate toxicity in most patients and provides similar patients' outcome compared to standard BEAesc treatment. Still, PET positivity after 2 cycles of BEAesc is related to a higher risk of disease progression, encouraging to develop new treatment options in patients with PET2 positive advanced stage HL. Disclosures Casasnovas: Roche: Consultancy, Research Funding; Takeda: Consultancy; Gilead: Consultancy. Salles:Celgene Corporation; Roche and Gilead Sciences: Research Funding; Calistoga Pharmaceuticals, Inc.; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceutica Products, L.P.; Roche: Consultancy; Celgene Corporation; Roche: Speakers Bureau. Dupuis:ABBVIE: Membership on an entity's Board of Directors or advisory committees; ROCHE: Speakers Bureau. Morschhauser:Genentech Inc./Roche: Other: Advisory boards. Tempescul:Gilead: Other: Export Board Committee.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.V126.23.577.577

Language: English

Publisher: American Society of Hematology

Publication Date: 2015

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 139, No. 15 ( 2022-04-14), p. 2338-2346

Abstract: Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency & gt;3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood.2021013526

Language: English

Publisher: American Society of Hematology

Publication Date: 2022

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 136, No. Supplement 1 ( 2020-11-5), p. 23-24

Abstract: Background AHL2011 study (NCT01358747) demonstrated that PET negativity after 2 cycles of upfront BEACOPPescalated (BEA) allows to switch to 4 cycles of ABVD 84% of patients (pts) with advanced Hodgkin lymphoma (HL) leading to reduce immediate treatment toxicity without loss of tumor control (Casasnovas RO, Lancet Oncol 2019). We report an updated follow-up of the study with a focus on the late treatment-related adverse events including secondary primary malignancies (SPM) and unfertility. Methods In AHL2011 823 patients aged 18-60 with a newly diagnosed advanced HL defined by an Ann Arbor stage III, IV or IIB with M/T & gt;0.33 or extranodal involvement were prospectively randomized between a standard arm (n=413) delivering 6 x BEA and a PET-driven arm (n=410) after 2 x BEA delivering 4 x ABVD in PET2- pts and 4 x BEA in PET2+ pts. In both arms PET performed after 4 cycles of chemotherapy had to be negative to complete the planned treatment. We aimed at excluding inferiority of the PET-driven arm of at least 10% compared to the standard arm which was achieved with the analysis on 10/2017. The data cutoff for the present analysis was 29 April 2019. A prospective fertility substudy for patients & lt;45y at time of randomization was performed analyzing: - In females, ovarian function using serum levels of FSH, estradiol and centralized anti-mullerian hormone (AMH) measurements. Acute premature ovarian insufficiency (POI) was defined as FSH & gt; 24 IU/L twice during 5y follow-up when available, with estradiol & lt; 50pg/ml, and low ovarian reserve (OR) by AMH & lt; 0.16ng/ml. - In males, FSH serum levels and sperm analysis. Results With a 5.6 year median follow-up, 5y PFS and OS were similar in both randomization arms (PFS: 87.5% vs 86.7% ; HR 1.07, 95%CI 0.74-1.57; p=0.67; OS: 97.7% in both arms; HR=1.012, 95%CI 0.50-2.10; p=0.53). In the whole cohort full interim PET assessment predicted patients PFS (5y PFS = 92.3% in PET2-/PET4-, 75.4% [HR= 3.26 ; 95%CI 18.3-5.77] in PET2+/PET4- and 46.5% [HR= 12.4 ; 95%CI : 7.31-19.51] in PET4+ pts respectively; p & lt;0.0001; figure 1) independently of IPS. OS was also impacted by interim PET results and PET2+/PET4- patients (5y OS : 93.5% ; HR=3.3, 95%CI : 1.07-10.1; p=0.036) and PET4+ patients (5y OS 91.9%; HR=3.756, 95%CI 1.07-13.18, p=0.038) had a significant lower OS than PET2-/PET4- patients (98.2%). 22 patients (2.7%) developped a secondary primary (SPM), 13 (3.2%) and 9 (2.2%) in the standard and experimental arms respectively. 424 males and 145 females with a median age 27y (16 - 45) entered the fertility sub-study. Baseline ovarian functions based on FSH and AMH levels were similar in the 70 and 75 female of the standard and PET-driven arms. During follow-up, 32 pts experienced POI (46.1% versus 14.5% in the standard and PET-driven arms, respectively). The risk of POI was significantly associated with both age, total dose of alkylating agents, and was reduced in the PET-driven arm (HR=0.20, 95%CI 0.08-0.5; p & lt;0.001). The risk of low OR was related to cumulative dose of etoposide & gt;5g (HR=0.36, 95%CI 0.14-0.96; p=0.04) but not to arms. In males, median baseline FSH levels were similar in both arms but 19 and 23% experienced severe oligospermia at baseline in standard (n=214) and PET-driven arms (n=210), respectively. Chemotherapy dramatically reduced sperm numeration in both arms but recovery occured more frequently in the PET-driven arm (severe oligospermia at 4-5 year: 50% vs 93%). A total of 84 patients (14.7%) reported pregnancies including 49 (17.2%) in the PET driven arm vs 35 (12.3%) in the standard arm (p=0.12) and required assisted reproductive technology treatment more frequently in the standard arm (23% vs 14%). Conclusions The prolonged follow-up confirms that the PET-driven strategy delivering 4 cycles of ABVD in PET negative patients after 2 cycles of BEA is non inferior compared to standard 6 cycles of BEA. PET4 provides additionnal prognostic information to PET2 and identifies patients with particularly poor prognosis. The PET-driven treatment allows to reduce significantly the risk of infertility in both men (recovery of oligospermia) and women (decreasing by 5 the risk of POI) and improves the chances of spontaneous pregnancy after completion of HL treatment. With the current follow-up the risk of SPM was low (2.7%) and similar in both arms. Disclosures Casasnovas: Roche: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; BMS: Consultancy, Honoraria; AMGEN: Consultancy, Honoraria; abbvie: Consultancy, Honoraria. Brice:Takeda: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; BMS: Honoraria; MSD: Honoraria; Roche: Other: TRAVEL, ACCOMMODATIONS, EXPENSES. Ghesquieres:Gilead: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; CELGENE: Consultancy, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Roche: Consultancy, Other: TRAVEL, ACCOMMODATIONS, EXPENSES; Janssen: Honoraria. Stamatoulas Bastard:Takeda: Consultancy; Celgene: Honoraria; Pfizer: Other: TRAVEL, ACCOMMODATIONS, EXPENSES. Dupuis:Henri Mondor University Hospital Creteil France: Current Employment. Gac:Roche: Consultancy; Takeda: Consultancy. Bouabdallah:Takeda: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Gilead Sciences: Consultancy, Honoraria. Morschhauser:Genentech, Inc.: Consultancy; Abbvie: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Servier: Consultancy; Celgene: Membership on an entity's Board of Directors or advisory committees; Epizyme: Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. André:Johnson & Johnson: Research Funding; Celgene: Other, Research Funding; Takeda: Consultancy; Bristol-Myers-Squibb: Consultancy, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); CHU UCL Namur, site Godinne, Yvoir, Belgium: Current Employment; Seattle Genetics: Consultancy; Novartis: Consultancy, Research Funding; Gilead: Consultancy, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Karyopharm: Consultancy; Abbvie: Consultancy; Amgen: Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Research Funding; Roche: Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Research Funding. Meignan:ROCHE: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company). Demeestere:Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; THERAMEX FERRING: Other: TRAVEL, ACCOMMODATIONS, EXPENSES.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2020-136056

Language: English

Publisher: American Society of Hematology

Publication Date: 2020

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7